ALTSTATION.IO

Thermo Fisher Scientific Inc. (TMO) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$542.45

Change

+0.02%

Market Cap

$203.80B

Avg Volume

2.0M

Company Overview

Thermo Fisher Scientific Inc. is a leading provider of life sciences solutions, analytical instruments, and specialty diagnostics. The company offers a wide range of products, including reagents, instruments, and consumables for research in biology and medicine, drug and vaccine development, and disease diagnosis. Their clientele includes academic institutions, pharmaceutical and biotechnology companies, clinical laboratories, and governmental agencies across North America, Europe, and Asia-Pacific.

As a market leader in the healthcare sector, Thermo Fisher holds a strong competitive position against key rivals like Siemens Healthineers, Abbott Laboratories, and PerkinElmer. Their extensive portfolio and commitment to innovation give them an edge, but they face threats from emerging competitors and pricing pressures in the diagnostics market. The integration of their product lines and services under well-known brands like Thermo Scientific and Applied Biosystems helps to bolster customer loyalty and market penetration.

Currently, Thermo Fisher is in a strong growth phase, driven by increased demand for diagnostics and life sciences solutions, particularly since the COVID-19 pandemic. The company is strategically focused on expanding its capabilities in biological testing and biopharmaceutical services. Recent milestones include significant investments in laboratory infrastructure and the acquisition of genetic testing firms, positioning them well for future opportunities in personalized medicine and advanced diagnostics. Overall, Thermo Fisher is poised for continued growth as they leverage their market position and expand into new areas.

Key Financials

Market Cap

$203.80B

Revenue

$44.56B

EBITDA

$11.15B

Gross Margin

41.7%

Profit Margin

15.0%

Revenue Growth

7.2%

Total Cash

$10.10B

Total Debt

$39.39B

Free Cash Flow

$4.36B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

30.58

Forward P/E

20.14

Beta

0.95

52-Week High

$643.99

52-Week Low

$385.46

EPS

$17.74

50-Day Avg

$591.69

200-Day Avg

$501.18

Price/Book

3.82

Technical Analysis

The overall trend for Thermo Fisher Scientific Inc. (TMO) over the past 52 weeks shows a decline, as evidenced by the current price of $542.45, which represents a -1.5% change. Key resistance is identified around $550, where multiple peaks occurred, and significant support is observed near $540, a level that has held up in recent trading. Notable price patterns include a period of consolidation from March through June, followed by a rally peaking in December before a sharp decline in early February. Recent momentum has been weak, with price falling from around $570 in January to the current level in February, indicating bearish pressure. Currently, TMO is near its support level, which implies potential risk if the price breaks below $540, potentially leading to further declines, while a bounce could test resistance again.

Recent News and Developments

Here’s a summary of the latest news and developments for Thermo Fisher Scientific Inc

(TMO) stock from January 31, 2026, to February 7, 2026:

1. Thermo Fisher Scientific Beats Q4 2025 Earnings, Issues 2026 Guidance

Thermo Fisher Scientific reported its fourth-quarter 2025 earnings on January 29, 2026, exceeding analyst expectations. The company announced quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of $6.43 per share, and revenues of $12.22 billion, surpassing the consensus estimate of $11.94 billion. For the full year 2025, revenue increased 4% to $44.56 billion. Following these results, the company provided its fiscal year 2026 guidance, projecting revenues between $46.3 billion and $47.2 billion, and adjusted earnings per share (EPS) in the range of $24.22 to $24.80. While revenue guidance was generally in line with analyst projections, the midpoint of the adjusted EPS outlook fell slightly below consensus estimates, which led to some premarket share fluctuations.

2. Analysts Maintain “Moderate Buy” Consensus Rating

As of February 6, 2026, Thermo Fisher Scientific maintains a consensus rating of “Moderate Buy” from analysts. The average rating score for the company is 2.95, based on 1 strong buy, 18 buy, and 2 hold ratings, with no sell ratings. The consensus price target for TMO stock stands at $633.68, indicating a potential upside of approximately 16.6% from its closing price of $543.46. Recent analyst reports from Citigroup, TD Cowen, and Barclays on January 30, 2026, provided an average price target of $672.67, implying an 17.99% upside from the stock’s trading price at that time.

Market Sentiment and Analyst Recommendations

Bull Case

TMO just beat Q4 earnings with $6.57 EPS versus $6.43 consensus, proving execution strength in a competitive biotech services market. Revenue guidance of $46.3-$47.2B for 2026 implies 3.8-5.8% growth, which is solid for a $203B company and reflects real demand in diagnostics and life sciences tools. The product pipeline is active — Orbitrap Astral Zoom, DynaDrive bioreactor, and FDA companion diagnostic approvals show innovation momentum across multiple segments. At 30.6x P/E, the valuation isn’t cheap, but 24 analysts recommend buy with average targets at $633-$672, suggesting 16-24% upside from current levels. The balance sheet supports growth with $10.1B cash and manageable debt, giving TMO firepower for acquisitions or R&D investment. The stock is near $540 support after a 8% pullback from $592 last week, creating a better risk-reward entry point for patient buyers.

Bear Case

The 7.2% revenue growth rate is decelerating from historical norms, and 2026 guidance suggests further slowdown to 3.8-5.8% — that’s a company hitting a maturity wall. At 30.6x P/E on 7.2% growth, TMO is expensive relative to peers and leaves little room for disappointment. The stock is down 4.6% over 12 months despite beating earnings, signaling that the market doesn’t believe in the growth narrative or valuation. Debt stands at $39.4B against only $10.1B cash, creating a 3.9x net debt position that limits financial flexibility during economic slowdowns. Recent weakness from $592 to $542 in one week shows fragile momentum, and breaking below $540 support could trigger further selling. The 2026 EPS guidance midpoint of $24.51 barely beats 2025 run-rate performance, meaning incremental growth is minimal even if the company executes perfectly.

What to Watch

Monitor Q1 2026 earnings in April for actual execution against the $46.3-$47.2B full-year revenue guide — any miss would validate bear concerns about growth deceleration. Watch whether TMO holds the $540 support level; a break below triggers technical selling and likely re-tests of $500-$520 range. Track the adoption rates of recent product launches, particularly the Orbitrap Astral Zoom and companion diagnostics, since these are the stated growth drivers for 2026. Pay attention to M&A activity — TMO historically grows through acquisitions, and a major deal announcement could re-energize the stock or signal management confidence. Keep tabs on analyst estimate revisions over the next 8 weeks; if target prices start dropping below $600, it signals consensus is losing faith in the bull case. Finally, watch the $550 resistance level closely — if TMO reclaims and holds above $550-$560, momentum could shift back to buyers and validate the 16% upside to consensus targets.

Analyst Consensus

BUY

Based on 24 analyst opinions

Low Target

$595.00

Mean Target

$666.46

High Target

$750.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 22, 2026

EPS (Trailing)

$17.74

Dividend Yield

32.0%

Payout Ratio

9.7%

Frequently Asked Questions

Is TMO a good stock to buy?

Yes, TMO is currently rated a “BUY” by analysts, with a target price of $666.46. With a solid market cap of $203.80 billion and a robust P/E ratio of 30.58, it’s well-positioned in the healthcare sector.

What is TMO’s price target?

The price target for Thermo Fisher Scientific Inc. is $666.46, suggesting significant upside potential from its current price of $542.45. This target indicates strong confidence from analysts in the company’s future growth.

Does TMO pay a dividend?

Yes, TMO offers a dividend yield of 32.0%. This makes it attractive for income-focused investors in addition to capital appreciation.

What has been TMO’s stock price range over the past year?

In the past year, TMO’s stock price has fluctuated between $385.46 and $643.99. This 52-week range highlights its volatility, offering opportunities for both gains and risk management.

What sectors does TMO operate in?

Thermo Fisher Scientific operates in the healthcare sector, specifically within the diagnostics and research industry. Its strong positioning here is crucial for long-term growth prospects.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.